Resistance to antivascular endothelial growth factor treatment in age-related macular degeneration

Drug Design, Development and Therapy

Volumn 7, Issue , 2013, Pages 485-490

  Tranos, Paris ^a   Vacalis, Athanasios ^a   Asteriadis, Solon ^a   Koukoula, Stavrenia ^a   Vachtsevanos, Athanasios ^a   Perganta, Georgia ^a   Georgalas, Ilias ^b  

^a Retina Centre   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Age related macular degeneration; AntiVEGF; Treatment

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; TRIAMCINOLONE; VASCULOTROPIN INHIBITOR; VERTEPORFIN; VASCULOTROPIN A;

DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ETHNICITY; EVIDENCE BASED MEDICINE; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HOMOZYGOSITY; HUMAN; INDOCYANINE GREEN ANGIOGRAPHY; LASER COAGULATION; OPTICAL COHERENCE TOMOGRAPHY; POLYPOIDAL CHOROIDAL VASCULOPATHY; PREVALENCE; RACE DIFFERENCE; RETINA DISEASE; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA VITELLIFORM DEGENERATION; RETINAL ANGIOMATOUS PROLIFERATION; RETINAL THICKNESS; REVIEW; SYSTEMATIC REVIEW; TACHYPHYLAXIS; TREATMENT FAILURE; TREATMENT RESPONSE; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; CHOROID DISEASES; DRUG RESISTANCE; GENETICS; MACULAR DEGENERATION;

CHOROID DISEASES; DRUG RESISTANCE; HUMANS; MACULAR DEGENERATION; TREATMENT FAILURE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84879139742     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S43470     Document Type: Review

References (51)

1. Kahn HA, Leibowitz HM, Ganley JP, etal. The Framingham Eye Study. I. Outline and major prevalence findings. Am J Epidemiol. 1977;106:17-32.
2. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology. 1992;99:933-943.
3. Klein BE, Klein R. Cataracts and macular degeneration in older Americans. Arch Ophthalmol. 1982;100:571-573.
4. Mitchell P, Smith W, Attebo K, Wang JJ. Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study. Ophthalmology. 1995;102:1450-1460.
5. Ferrara N, Gerber HP, Lecouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669-676.
6. Fine SL, Berger JW, Maguire MG, Ho AC. Age-related macular degeneration. N Engl J Med. 2000;342:483-492.
7. Aiello LP, Avery RL, Arrigg PG, etal. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480-1487.
8. Adamis AP, Shima DT, Tolentino MJ, etal. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol. 1996;114: 66-71.
9. Presta LG, Chen H, O'Connor SJ, etal. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57:4593-4599.
10. Hurwitz H, Fehrenbacher L, Novotny W, etal. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
11. Manoj SM. Why does anti VEGF treatment fail in age related macular degeneration (AMD). Kerala Journal of Ophthalmology. 2011.
12. Sho K, Takahashi K, Yamada H, etal. Polypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristics. Arch Ophthalmol. 2003;121:1392-1396.
13. Cho M, Barbazetto IA, Freund KB. Refractory neovascular age-related macular degeneration secondary to polypoidal choroidal vasculopathy. Am J Ophthalmol. 2009;148:70-78. e1.
14. Seddon JM, Francis PJ, George S, Schultz DW, Rosner B, Klein ML. Association of CFH Y402H and LOC387715A69S with progression of age-related macular degeneration. JAMA. 2007;297:1793-1800.
15. Chan WM, Lam DS, Lai TY, etal. Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series. Ophthalmology. 2004;111:1576-1584.
16. Eandi CM, Ober MD, Freund KB, Slakter JS, Yannuzzi LA. Selective photodynamic therapy for neovascular age-related macular degeneration with polypoidal choroidal neovascularization. Retina. 2007;27:825-831.
17. Wakabayashi T, Gomi F, Sawa M, Tsujikawa M, Tano Y. Marked vascular changes of polypoidal choroidal vasculopathy after photodynamic therapy. Br J Ophthalmol. 2008;92:936-940.
18. Gomi F, Sawa M, Sakaguchi H, etal. Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol. 2008;92:70-73.
19. Koh AH, Chen LJ, Chen SJ, etal. Polypoidal choroidal vasculopathy: evidence-based guidelines for clinical diagnosis and treatment. Retina. 2013;33:686-716.
20. Yannuzzi LA, Negrao S, Iida T, etal. Retinal angiomatous proliferation in age-related macular degeneration. Retina. 2001;21:416-434.
21. Freund KB, Ho IV, Barbazetto IA, etal. Type 3 neovascularization: the expanded spectrum of retinal angiomatous proliferation. Retina. 2008;28:201-211.
22. Scott AW, Bressler SB. Retinal angiomatous proliferation or retinal anastomosis to the lesion. Eye (Lond). 2010;24:491-496.
23. Cohen SY, Creuzot-Garcher C, Darmon J, etal. Types of choroidal neovascularisation in newly diagnosed exudative age-related macular degeneration. Br J Ophthalmol. 2007;91:1173-1176.
24. Maruko I, Iida T, Saito M, Nagayama D, Saito K. Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol. 2007;144:15-22.
25. Hartnett ME, Weiter JJ, Staurenghi G, Elsner AE. Deep retinal vascular anomalous complexes in advanced age-related macular degeneration. Ophthalmology. 1996;103:2042-2053.
26. Bottoni F, Massacesi A, Cigada M, Viola F, Musicco I, Staurenghi G. Treatment of retinal angiomatous proliferation in age-related macular degeneration: a series of 104 cases of retinal angiomatous proliferation. Arch Ophthalmol. 2005;123:1644-1650.
27. Bressler NM. Retinal anastomosis to choroidal neovascularization: a bum rap for a difficult disease. Arch Ophthalmol. 2005;123:1741-1743.
28. Slakter JS, Yannuzzi LA, Schneider U, etal. Retinal choroidal anastomoses and occult choroidal neovascularization in age-related macular degeneration. Ophthalmology. 2000;107:742-753; discussion, 753-754.
29. Kuroiwa US, Arai J, Gaun S, Iida T, Yoshimura N. Rapidly progressive scar formation after transpupillary thermotherapy in retinal angiomatous proliferation. Retina. 2003;23:417-420.
30. Sakimoto AS, Gomi F, Sakaguchi H, Tano Y. Recurrent retinal angiomatous proliferation after surgical ablation. Am J Ophthalmol. 2005;139:917-918.
31. Shiragami C, Iida T, Nagayama D, Baba T, Shiraga F. Recurrence after surgical ablation for retinal angiomatous proliferation. Retina. 2007;27:198-203.
32. Boscia F, Furino C, Sborgia L, Reibaldi M, Sborgia C. Photodynamic therapy for retinal angiomatous proliferations and pigment epithelium detachment. Am J Ophthalmol. 2004;138:1077-1079.
33. Silva RM, Cachulo ML, Figueira J, De Abreu JR, Cunha-Vaz JG. Chorioretinal anastomosis and photodynamic therapy: a two-year follow-up study. Graefes Arch Clin Exp Ophthalmol. 2007;245:1131-1139.
34. Saito M, Shiragami C, Shiraga F, Nagayama D, Iida T. Combined intravitreal bevacizumab and photodynamic therapy for retinal angiomatous proliferation. Am J Ophthalmol. 2008;146:935-941. e1.
35. Rouvas AA, Papakostas TD, Ntouraki A, Douvali M, Vergados I, Ladas ID. Photodynamic therapy, ranibizumab, and ranibizumab with photodynamic therapy for the treatment of polypoidal choroidal vasculopathy. Retina. 2011;31:464-474.
36. Shirakata Y, Shiragami Y, Shiragami C, etal. One-year results of bevacizumab intravitreal and posterior sub-Tenon injection of triamcinolone acetonide with reduced laser fluence photodynamic therapy for retinal angiomatous proliferation. Jpn J Ophthalmol. 2012;56:599-607.
37. Rosenfeld PJ, Brown DM, Heier JS, etal. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355: 1419-1431.
38. Keane PA, Liakopoulos S, Ongchin SC, etal. Quantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2008;49:3115-3120.
39. Eghoj MS, Sorensen TL. Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol. 2012;96:21-23.
40. Gasperini JL, Fawzi AA, Khondkaryan A, etal. Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation. Br J Ophthalmol. 2012;96:14-20.
41. Forooghian F, Chew EY, Meyerle CB, Cukras C, Wong WT. Investigation of the role of neutralizing antibodies against bevacizumab as mediators of tachyphylaxis. Acta Ophthalmol. 2011;89:e206-e207.
42. Schaal S, Kaplan HJ, Tezel TH. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration. Ophthalmology. 2008;115:2199-2205.
43. Swaroop A, Chew EY, Rickman CB, Abecasis GR. Unraveling a multifactorial late-onset disease: from genetic susceptibility to disease mechanisms for age-related macular degeneration. Annu Rev Genomics Hum Genet. 2009;10:19-43.
44. Feng X, Xiao J, Longville B, etal. Complement factor H Y402H and C-reactive protein polymorphism and photodynamic therapy response in age-related macular degeneration. Ophthalmology. 2009;116: 1908-1912. e1901.
45. Brantley MA, Fang AM, King JM, Tewari A, Kymes SM, Shiels A. Association of complement factor H and LOC387715genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. Ophthalmology. 2007;93:610-613.
46. Lee AY, Raya AK, Kymes SM, Shiels A, Brantley MA. Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmology. 2009;93:610-613.
47. Chen H, Yu KD, Xu GZ. Association between variant Y402H in age-related macular degeneration (AMD) susceptibility gene CFH and treatment response of AMD: a meta-analysis. PLoS One. 2012;7(8):e42464. doi: 10.1371/journal.pone.0042464. Epub 2012 Aug 14.
48. Teper SJ, Nowinska A, Pilat J, Palucha A, Wylegala E. Involvement of genetic factors in the response to a variable-dosing ranibizumab treatment regimen for age-related macular degeneration. Mol Vis. 2010;16: 2598-2604.
49. Orlin A, Hadley D, Chang W, etal. Association between high-risk disease loci and response to anti-vascular endothelial growth factor treatment for wet age related macular degeneration. Retina. 2012;32:4-9.
50. Stewart MW, Rosenfeld PJ, Penha FM, etal. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor trap-eye). Retina. 2011;32:434-457.
51. Lee SJ, Koh HJ. Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for exudative age-related macular degeneration. Ophthalmology. 2011;118:101-110.